

## OFFICE OF FLANCE IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTN: FINANCE DEPARTMENT REFUND DIVISION

In re the Patent Application of **FLAD** 

Serial No.: 09/700,906

Filed: November 22, 2000

Examiner: Unknown

For: ANTISENSE OLIGONUCLEIOTIDES

FOR TREATING PROLIFERATING CELLS

US PATENT & TRADEMARK

Group Art Unit: Unknown

## REQUEST FOR REFUND

Commissioner of Patents and Trademarks Washington, D. C. 20231

Sir:

Our deposit account was erroneously charged \$270 for multiple dependent claims in the above referenced application. However, the preliminary amendment filed with the application on November 21, 2000 changed the dependency of these claims so that NO multiple dependent claims remain. A copy of the preliminary amendment as filed and the postcard receipt are enclosed.

Therefore, the Patent and Trademark Office is requested to make a credit to our deposit account 50-0687 in reference 62-661 in the amount of \$270.

This paper is being submitted in duplicate for the convenience of the Finance Branch.

Respectfully submitted,

Registration No. 35,950

Manelli Denison & Selter PLLC 2000 M Street, N. W. 7th Floor Washington, DC 20002-3307 (202) 261-1000

ATTORNEY'S DOCKET NUMBER ARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1390 (REV 10-2000) MAY 1 7 2002 661-50303 TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (If known, see 37 CFR 1.5) A FILING UNDER 35 U.S.C. 371 PRIORITY DATE CLAIMED INTERNATIONAL FILING DATE INTERNATIONAL APPLICATION NO. 22 May 1998 20 May 1999 PCT/EP99/03451 ANTISENSE OLIGONUCLEOTIDES FOR TREATING PROLIFERATING CELLS TITLE OF INVENTION Flad, Hans-Dieter; Bohle, Andreas; APPLICANT(S) FOR DO/EO/US Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). The US has been elected by the expiration of 19 months from the priority date (PCT Article 31). 4. X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) 5. X is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 16 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. A substitute specification. A change of power of attorney and/or address letter. 16. X Other items or information: Amend claims 4-8, 10 and 13 as follows, prior to calculating claim fees and without prejudice: line 1, delete "bis 3". Claim 4. line 1, delete "bis 4" Claim 5, line 1, delete "bis 5" Claim 6, line 1, delete "bis 6" Claim 7, line 1, delete "bis 7" Claim 8 Claim 10, line 1, delete "bis 8" Claim 13, line l, delete "oder 12". The Claims have been amended to remove multiple dependency only. No claims have been amended to overcome prior art.